The Prostaglandin E2 Receptor EP1 Subtype pipeline drugs market research report outlays comprehensive information on the Prostaglandin E2 Receptor EP1 Subtype targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Prostaglandin E2 Receptor EP1 Subtype pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Central Nervous System, Gastrointestinal, and Infectious Disease which include the indications Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Raynauds Disease, Post-Operative Pain, Pain, Oral Mucositis, and Coronavirus Disease 2019 (COVID-19). It also reviews key players involved in Prostaglandin E2 Receptor EP1 Subtype targeted therapeutics development with respective active and dormant or discontinued products.
The Prostaglandin E2 Receptor EP1 Subtype pipeline targets constitutes close to 15 molecules. Out of which, approximately 14 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, Phase I, Preclinical, and Discovery stages are 1, 4, 2, 5, and 1 respectively. Similarly, the universities portfolio in Phase III comprises 1 molecule.
Prostaglandin E2 Receptor EP1 Subtype overview
Prostaglandin E2 receptor EP1 subtype (PTGER1) is a receptor for prostaglandin E2 (PGE2) and is a member of the G protein-coupled receptor family. The activity of this receptor is mediated by G(q) proteins which activates a phosphatidylinositol-calcium second messenger system that raises cellular cytosolic calcium levels, thereby regulating calcium-sensitive cell signal pathways that promote the activation of certain protein kinase C isoforms. The activation of protein kinases C feeds back to phosphorylate and thereby desensitize the activated EP1 receptor, leading to cellular function responses.
For a complete picture of Prostaglandin E2 Receptor EP1 Subtype’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
